AstraZeneca bets on continued oncology demand for 2026 growth
AstraZeneca expects profits to increase in 2026, as it counts on strong demand for its oncology portfolio continuing despite geopolitical …
Post
-
-
AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals
Under the three-year deal, AbbVie agreed to lower prices on certain Medicaid drugs and expand distribution through the TrumpRx direct-to-patient …
-
RWD and RWE are rewriting how we design and run trials
Traditional randomized controlled trials (RCTs) have long been the gold standard for testing new therapies, but they are increasingly strained …
-
A New Strategic Blueprint: Designing Smarter Early Phase Trials in Oncology
Cancer drugs form one of the most dynamic segments of pharmaceuticals, powered by rising incidence, ageing populations, deeper cancer biology, …
-
By the Numbers: Oncology Trial Activation Timelines and Global Reach
The volume of current activity in the oncology space is enormous. GlobalData’s clinical trial database – a repository of data …
-
REGENXBIO receives FDA response for RGX-121 application
REGENXBIO has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) related to its biologics licence …
-
Takeda and Iambic announce $1.7bn deal to advance small molecule programmes
Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a …
-
Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout
Eli Lilly is acquiring in vivo cell therapy-focused biotech, Orna Therapeutics, in an immunology deal worth up to $2.4bn. Through the …
-
Novo sues Hims & Hers despite Wegovy pill offering U-turn
Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though Novo and …
-
Robots and pharma logistics: is the future inside a McKesson warehouse?
Across the pharmaceutical sector, governments in major markets are placing increasing pressure on the industry for full visibility and traceability …
-
Pharma eyes AI deals to stem lost revenues from patent expirations
Pharmaceutical giants are employing an array of tactics to minimise the falling revenues that come when patents expire on their …
-
FDA’s commissioner vouchers prompt questions about award process
In June 2025, the US Food and Drug Administration (FDA) announced the Commissioner's National Priority Voucher (CNPV) pilot programme. The regulatory …
-
Magazine: Smart and connected packaging
With the recent conclusion of PharmaPack 2026, this month’s magazine is focused on the key messaging that emanated from the event. With the …
-
Innovent and Lilly to advance new oncology and immunology medicines
Innovent Biologics and Eli Lilly and Company have entered a strategic collaboration agreement to accelerate the global development of new …
-
Novartis starts construction on new research facility in San Diego, US
Novartis has commenced construction on its new global biomedical research centre in San Diego, California, US, aimed at expanding its …
